KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) EBIT (2017 - 2025)

Historic EBIT for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $1.1 billion.

  • Takeda Pharmaceutical's EBIT fell 1191.58% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.8 billion, marking a year-over-year increase of 4197.23%. This contributed to the annual value of $2.2 billion for FY2025, which is 5150.85% up from last year.
  • Takeda Pharmaceutical's EBIT amounted to $1.1 billion in Q4 2025, which was down 1191.58% from $6.8 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's EBIT peaked at $6.8 billion during Q3 2025, and registered a low of -$67.9 million during Q1 2024.
  • For the 5-year period, Takeda Pharmaceutical's EBIT averaged around $1.9 billion, with its median value being $1.3 billion (2023).
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 10533.05% in 2024, then skyrocketed by 378809.27% in 2025.
  • Over the past 5 years, Takeda Pharmaceutical's EBIT (Quarter) stood at $1.0 billion in 2021, then increased by 1.53% to $1.0 billion in 2022, then surged by 51.96% to $1.6 billion in 2023, then decreased by 21.24% to $1.2 billion in 2024, then dropped by 11.92% to $1.1 billion in 2025.
  • Its EBIT was $1.1 billion in Q4 2025, compared to $6.8 billion in Q3 2025 and $2.3 billion in Q2 2025.